🇺🇸 FDA
Patent

US 12109239

Methods for production of human hemogenic endothelial cells from pluripotent stem cells and compositions thereof

granted A61KA61K35/19A61P

Quick answer

US patent 12109239 (Methods for production of human hemogenic endothelial cells from pluripotent stem cells and compositions thereof) held by Astellas Institute for Regenerative Medicine expires Mon Oct 03 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Astellas Institute for Regenerative Medicine
Grant date
Tue Oct 08 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 03 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
20
CPC classes
A61K, A61K35/19, A61P, A61P17/02, A61P33/06